Irene Perlich's Insider Trades & SAST Disclosures
Irene Perlich's most recent trade in Ngm Biopharmaceuticals Inc was a trade of 50,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on April 5, 2024.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Irene Perlich.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Ngm Biopharmaceuticals Inc | Irene Perlich | Principal Accounting Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 05 Apr 2024 | 50,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Ngm Biopharmaceuticals Inc | Irene Perlich | Principal Accounting Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 05 Apr 2024 | 35,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Ngm Biopharmaceuticals Inc | Irene Perlich | Principal Accounting Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 05 Apr 2024 | 30,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Ngm Biopharmaceuticals Inc | Irene Perlich | Principal Accounting Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 05 Apr 2024 | 20,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Ngm Biopharmaceuticals Inc | Irene Perlich | Principal Accounting Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 05 Apr 2024 | 17,500 | 0 | - | - | Stock Option (Right to Buy) | |
| Ngm Biopharmaceuticals Inc | Irene Perlich | Principal Accounting Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 05 Apr 2024 | 7,500 | 0 | - | - | Restricted Stock Unit | |
| Ngm Biopharmaceuticals Inc | Irene Perlich | Principal Accounting Officer | 05 Apr 2024 | 6,284 | 0 (0%) | 0% | - | Common Stock | ||
| Ngm Biopharmaceuticals Inc | Irene Perlich | PRINCIPAL ACCOUNTING OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.34 per share. | 16 Jan 2024 | 1,025 | 8,975 (0%) | 0% | 1.3 | 1,374 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges